Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Revance Therapeutics Inc (NASDAQ:RVNC)

25.55
Delayed Data
As of 4:00pm ET
 -0.30 / -1.16%
Today’s Change
12.35
Today|||52-Week Range
28.30
+23.43%
Year-to-Date
Biotech Movers: Sangamo, Epizyme, Revance
Jun 21 / TheStreet.com - Paid Partner Content
 

Today’s Trading

Previous close25.85
Today’s open26.10
Day’s range25.40 - 26.10
Volume202,369
Average volume (3 months)199,477
Market cap$782.6M
Dividend yield--
Data as of 4:00pm ET, 06/28/2017

Growth & Valuation

Earnings growth (last year)-5.30%
Earnings growth (this year)-23.27%
Earnings growth (next 5 years)--
Revenue growth (last year)0.00%
P/E ratioNM
Price/Sales1,939.92
Price/Book4.18

Competitors

 Today’s
change
Today’s
% change
AMPHAmphastar Pharmaceut...+0.42+2.43%
ADROAduro Biotech Inc+0.20+1.83%
LCILannett Company Inc+0.30+1.46%
HRTXHeron Therapeutics I...+0.25+1.81%
Data as of 4:01pm ET, 06/28/2017

Financials

Next reporting dateAugust 15, 2017
EPS forecast (this quarter)-$0.97
Annual revenue (last year)$300.0K
Annual profit (last year)-$89.3M
Net profit margin-29,756.67%

Profile

Sector
Health Technology
Industry
Pharmaceuticals: Other
President, Chief Executive Officer &
Director
L. Daniel Browne
Chief Operating Officer
Abhay Joshi
Corporate headquarters
Newark, California

Forecasts